Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5372908 | 0.76 | MEN1 (0.63) | MEN1KMT2A | |
| SCHEMBL5372977 | 0.74 | KMT2A (0.43) | MEN1KMT2A | |
| SCHEMBL27787232 | 0.74 | PARP1 (0.44) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8499722 | 0.73 | PARP1 (0.43) | MEN1KMT2A | |
| SCHEMBL28396264 | 0.71 | L3MBTL1 (0.41) | MEN1KMT2A | |
| SCHEMBL28478142 | 0.71 | CES2 (0.55) | MEN1KMT2A | |
| SCHEMBL8766190 | 0.71 | CA12 (0.46) | MEN1KMT2A | |
| SCHEMBL18762041 | 0.71 | GABRA1 (0.32) | — | |
| SCHEMBL28766354 | 0.67 | GABRA1 (0.35) | MEN1KMT2A | |
| SCHEMBL26037 | 0.66 | ALDH1A1 (0.53) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| EP-3813827-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | STING1, CGAS, MAVS | MEN1 504/4885KMT2A 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.